Literature DB >> 23105949

Substance-use disorders in adolescents and adults with ADHD: focus on treatment.

Timothy E Wilens1, Nicholas R Morrison.   

Abstract

A high prevalence of comorbidity of ADHD and substance-use disorders (SUDs) has been shown in the literature. In this article, the literature for the treatment of adolescents and adults with co-occurring ADHD and SUD is examined. Findings from pharmacotherapy suggest mild improvement in ADHD without demonstrable changes in SUD unless the addiction was stabilized prior to treating the ADHD. No unique adverse effects, worsening of SUD, misuse or diversion of stimulants are reported in the included studies. Treating ADHD pharmacologically in individuals with ADHD plus SUD only has a modest impact on ADHD and SUD that is not observed in controlled trials. Limited data in adults with ADHD and brief abstinence of their SUD showed improvements in both ADHD and SUD with treatment. Further studies of cognitive behavioral therapy, sequencing of therapies and longer term treatment outcomes for groups with ADHD and active SUD are necessary.

Entities:  

Year:  2012        PMID： 23105949      PMCID： PMC3480177          DOI： 10.2217/npy.12.39

Source DB:  PubMed          Journal:  Neuropsychiatry (London)        ISSN： 1758-2008


  65 in total

1.  Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder.

Authors:  F R Levin; S M Evans; H D Kleber
Journal:  Psychiatr Serv       Date:  1999-08       Impact factor: 3.084

Review 2.  Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Authors:  John Grabowski; James Shearer; John Merrill; S Stevens Negus
Journal:  Addict Behav       Date:  2004-09       Impact factor: 3.913

3.  Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey.

Authors:  Sean Esteban McCabe; John R Knight; Christian J Teter; Henry Wechsler
Journal:  Addiction       Date:  2005-01       Impact factor: 6.526

Review 4.  ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.

Authors:  Scott H Kollins
Journal:  J Atten Disord       Date:  2008-01-11       Impact factor: 3.256

5.  Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders.

Authors:  Ramon Solhkhah; Timothy E Wilens; Jeanine Daly; Jefferson B Prince; Stephanie L Van Patten; Joseph Biederman
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-10       Impact factor: 2.576

6.  Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.

Authors:  Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-08-15       Impact factor: 4.492

7.  An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder.

Authors:  Eugene C Somoza; Theresa M Winhusen; T Peter Bridge; John P Rotrosen; Douglas G Vanderburg; Judy M Harrer; Juris P Mezinskis; Margaret A Montgomery; Domenic A Ciraulo; Lawson R Wulsin; Jera A Barrett
Journal:  J Addict Dis       Date:  2004

8.  Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

Authors:  Timothy E Wilens; Lenard A Adler; Margaret D Weiss; David Michelson; Janet L Ramsey; Rodney J Moore; Didier Renard; Kathleen T Brady; Paula T Trzepacz; Leslie M Schuh; Lisa M Ahrbecker; Louise R Levine
Journal:  Drug Alcohol Depend       Date:  2008-04-09       Impact factor: 4.492

9.  A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.

Authors:  Paula D Riggs; Shannon K Hall; Susan K Mikulich-Gilbertson; Michelle Lohman; Ashley Kayser
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-04       Impact factor: 8.829

10.  Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study.

Authors:  F R Levin; S M Evans; D M McDowell; H D Kleber
Journal:  J Clin Psychiatry       Date:  1998-06       Impact factor: 4.384
View more
  6 in total

1.  International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Authors:  Cleo L Crunelle; Wim van den Brink; Franz Moggi; Maija Konstenius; Johan Franck; Frances R Levin; Geurt van de Glind; Zsolt Demetrovics; Corné Coetzee; Mathias Luderer; Arnt Schellekens; Frieda Matthys
Journal:  Eur Addict Res       Date:  2018-03-06       Impact factor: 3.015

2.  Attention Deficit Hyperactivity Disorder (ADHD) Subtypes, Co-Occurring Psychiatric Symptoms and Sexual Risk Behaviors among Adolescents Receiving Substance Abuse Treatment.

Authors:  Timothy Regan; Jonathan Tubman
Journal:  Subst Use Misuse       Date:  2019-09-10       Impact factor: 2.164

Review 3.  Male adolescent substance use disorder and attention-deficit hyperactivity disorder: a review of the literature.

Authors:  Robert Eme
Journal:  ISRN Addict       Date:  2012-11-28

4.  Acceptance and commitment therapy for clients institutionalized for severe substance-use disorder: a pilot study.

Authors:  Gabriella Svanberg; Ingrid Munck; Maria Levander
Journal:  Subst Abuse Rehabil       Date:  2017-07-26

5.  Structural brain morphometry as classifier and predictor of ADHD and reward-related comorbidities.

Authors:  Daan van Rooij; Yanli Zhang-James; Jan Buitelaar; Stephen V Faraone; Andreas Reif; Oliver Grimm
Journal:  Front Psychiatry       Date:  2022-09-12       Impact factor: 5.435

6.  Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients. A 5-Year Follow-Up Study.

Authors:  Alessandro Pallucchini; Marco Carli; Angelo G I Maremmani; Marco Scarselli; Giulio Perugi; Icro Maremmani
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.